The following patient inclusion criteria were set: (i) ICU patients from the four participating hospitals who were newly diagnosed with AbVAP between January 2014 and October 2015, as confirmed by the hospital database and (ii) an age older than 18 years. A. baumannii was identified using a Phoenix TM -100 automated microbiology system (Becton Dickinson and Company, Franklin Lakes, NJ, USA). The following patient data were recorded: age, gender, length of ICU stay, disease severity at the time of diagnosis, surgery within 1 month before diagnosis, underlying systemic diseases, invasive procedures, antimicrobial susceptibility of A. baumannii to tigecycline, blood culture findings, medical imaging features, and antimicrobial treatment after obtaining culture results. Subsequent bacteremia was defined as at least one A. baumannii-positive blood culture in the absence of a different infection source and at least one A. baumannii-positive tracheal aspirate culture after the development of newly diagnosed AbVAP. Other bacterial co-pathogens were also investigated. The study outcome was overall 30-day mortality in the ICU. All patients were included in a survival follow-up until death or 30 days after the onset of VAP.
All study data were processed using SPSS software version 22.0 (SPSS, Inc., Chicago, IL, USA .0 for survivors and nonsurvivors respectively, P < 0.001). Cardiovascular disease was the most common underlying systemic disease, occurring in 69.0% of the patients. Tracheostomy was the most common invasive procedure performed during the hospital stay (111, 70.3%).
Forty-eight patients (30.4%) in our study were infected with co-pathogens, of which the most common were Pseudomonas aeruginosa (36, 22.8%) and Klebsiella pneumoniae (15, 9.5%). Notably, the frequency of tigecycline-resistant A. baumannii increased to 16.5% in our study population. Thirteen patients were found to develop subsequent A. baumannii bacteremia, and all cases involved multidrug resistance. However, only 54.4% of the patients received appropriate antibiotic therapy, as shown in Table 1 .
The logistic regression analysis included all factors that received P < 0.20, as shown in Table 1 O u r r e s e a r c h d e m o n s t r a t e d t h a t s u b s e q u e n t multidrug-resistant bacteremia is a risk factor for short-term mortality among patients with AbVAP in the ICU. This finding may be attributed to the increased usage of a central venous catheter before bacteremia onset (76.9% [10/13] vs. 40.0% [58/145], P = 0.010). [4] Therefore, physicians should emphasize the importance of barrier precautions, as well as appropriate antibiotic treatment. However, our This study had some inherent limitations of note. Particularly, all clinical information related to the risk factors was collected retrospectively, which restricts the generalization of our findings to additional patients. Further prospective studies should be conducted.
In conclusion, AbVAP often develops as a nosocomial infection and is associated with a high mortality rate. Limitations on central venous catheter use, the avoidance of subsequent A. baumannii bacteremia, and the judicious use of antibiotics may reduce the mortality associated with AbVAP in the ICU. 
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